Hospice care under private equity shows longer patient stays and increased Medicare costs
A new study reveals that hospices acquired by private equity firms saw an average increase of $993 in Medicare spending per patient encounter and extended patient stays by 6.3 days, despite no rise in the number of visits. The findings suggest that financial ownership models may influence care duration and cost without improving clinical outcomes. Researchers caution that such trends could strain public healthcare budgets.
A recent study has found that hospices acquired by private equity firms experienced a significant rise in Medicare spending per patient encounter—averaging $993 more—while also extending patient stays by 6.3 days, even though the number of visits remained unchanged. These findings highlight a growing trend in healthcare ownership where financial incentives may influence care duration and cost without corresponding improvements in clinical outcomes. The data suggest that private equity’s profit-driven model could be reshaping end-of-life care delivery, potentially prioritizing revenue generation over patient-centered metrics. While the study does not specify exact locations or timeframes for the observations, it underscores a broader concern about how ownership structures affect public health spending.
The shift toward private equity acquisition of hospice providers reflects a larger trend in healthcare consolidation, where investor-owned entities seek to scale operations and maximize returns. This model may incentivize longer patient stays as a way to increase billing, even if clinical need does not justify extended care. The study’s authors caution that such patterns could place increasing pressure on Medicare budgets, particularly as the U.S. population ages and demand for hospice services grows. While no specific organizations or individuals are named in the findings, the implications point to a tension between financial performance and ethical care delivery. What remains
The findings raise concerns about how financial incentives may distort care delivery in vulnerable populations. As private equity expands into healthcare services like hospice, there’s a risk that cost efficiency becomes secondary to revenue growth, potentially affecting patient autonomy and quality of life during final days. This could disproportionately impact Medicare beneficiaries, who rely on public funding for end-of-life care, and may strain the sustainability of federal health programs. If longer stays without improved outcomes become standard, it could lead to broader inefficiencies in healthcare resource allocation. A comparable case is the earlier expansion of private equity in nursing homes, where similar concerns emerged about reduced staffing and increased billing practices. That experience suggests such models may initially boost profits but erode care quality over time. What’s next may depend on whether policymakers treat hospice as a clinical service or a financial as